These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 33141318

  • 1. The association between anogenital distance and benign prostatic hyperplasia related lower urinary tract symptoms in Chinese aging men.
    Lu Y, Fan S, Song Y, Liu K, Zhou K, Kang J, Wang S, Yang Y, Liu X.
    World J Urol; 2021 Jul; 39(7):2645-2653. PubMed ID: 33141318
    [Abstract] [Full Text] [Related]

  • 2. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men.
    Lee JH, Kim Y, Park YW, Lee DG.
    J Sex Med; 2014 May; 11(5):1309-15. PubMed ID: 24612680
    [Abstract] [Full Text] [Related]

  • 3. The relationship between anogenital distance and benign prostate hyperplasia-related lower urinary tract symptoms.
    Kutluhan MA, Şahin A, Ürkmez A, Toprak T, Akgül K, Topaktaş R, Sertkaya Z, Verit A.
    Andrologia; 2020 Aug; 52(7):e13589. PubMed ID: 32271471
    [Abstract] [Full Text] [Related]

  • 4. [The results of the multicenter prospective comparative study of Androgel in men with endogenous testosterone deficiency and lower urinary tract symptoms, associated with benign prostate hyperplasia (POTOK)].
    Kogan MI, Avadieva NE, Gevorkyan LS, Loginov YA, Metelkin AM, Mitin AA, Patrikeev AA.
    Urologiia; 2023 May; (2):32-40. PubMed ID: 37401702
    [Abstract] [Full Text] [Related]

  • 5. Relationship between Metabolic Syndrome and Predictors for Clinical Benign Prostatic Hyperplasia Progression and International Prostate Symptom Score in Patients with Moderate to Severe Lower Urinary Tract Symptoms.
    Zhao S, Chen C, Chen Z, Xia M, Tang J, Shao S, Yan Y.
    Urol J; 2016 Jun 28; 13(3):2717-26. PubMed ID: 27351328
    [Abstract] [Full Text] [Related]

  • 6. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV, Mete UK, Mandal AK, Singh SK.
    J Sex Med; 2014 Jan 28; 11(1):187-96. PubMed ID: 24165272
    [Abstract] [Full Text] [Related]

  • 7. Potential role of glutathione S-transferase P1 gene polymorphism and metabolic syndrome in lower urinary tract symptoms attributed to benign prostatic hyperplasia.
    Zhang W, Li Z, Liu M, Mu Y, He J, Chen P, Liu D, Chen K, Che B, Xu S, Zhang H, Tang K.
    World J Urol; 2021 Dec 28; 39(12):4413-4419. PubMed ID: 34228163
    [Abstract] [Full Text] [Related]

  • 8. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G, Broderick G, Roehrborn CG, Xu L, Wong D, Viktrup L.
    BJU Int; 2013 Nov 28; 112(7):990-7. PubMed ID: 23937669
    [Abstract] [Full Text] [Related]

  • 9. The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms.
    Lee YC, Juan YS, Liu CC, Bao BY, Wang CJ, Wu WJ, Huang CN, Huang SP.
    BJU Int; 2016 Aug 28; 118(2):313-9. PubMed ID: 26940040
    [Abstract] [Full Text] [Related]

  • 10. Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Viktrup L, Hayes RP, Wang P, Shen W.
    BMC Urol; 2012 Nov 07; 12():30. PubMed ID: 23134716
    [Abstract] [Full Text] [Related]

  • 11. Assesment of anogenital distance as a marker in diagnosis of prostate cancer.
    Sahin A, Kutluhan MA, Toprak T, Vural Y, Ürkmez A, Akan S, Verit A.
    Arch Ital Urol Androl; 2019 Oct 02; 91(3):. PubMed ID: 31577097
    [Abstract] [Full Text] [Related]

  • 12. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L.
    J Sex Med; 2013 Aug 02; 10(8):2044-52. PubMed ID: 23782459
    [Abstract] [Full Text] [Related]

  • 13. Association of lower urinary tract symptom/benign prostatic hyperplasia measures with international index of erectile function 5 in middle-aged policemen of Korea and the role of metabolic syndrome and testosterone in their relationship.
    Lee JH, Kwon H, Park YW.
    Urology; 2013 Nov 02; 82(5):1008-12. PubMed ID: 24041675
    [Abstract] [Full Text] [Related]

  • 14. Rezum water vapor therapy for patients with mild, moderate, or severe lower urinary tract symptoms: A retrospective study in a multiethnic population.
    Babar M, Loloi J, Tang K, Singh S, Ines M, Patel RD, Iqbal N, Ciatto M.
    Prostate; 2023 May 02; 83(7):713-721. PubMed ID: 36879380
    [Abstract] [Full Text] [Related]

  • 15. Is periurethral calcification associated with urinary flow rate and symptom severity in men with lower urinary tract symptoms-benign prostatic hyperplasia? A retrospective review.
    Han JH, Kwon JK, Lee JY, Kang DH, Choi HC, Lee JS, Cho KS.
    Urology; 2015 May 02; 85(5):1156-1161. PubMed ID: 25818911
    [Abstract] [Full Text] [Related]

  • 16. Effect of preoperative detrusor underactivity on long-term surgical outcomes of photovaporization and holmium laser enucleation in men with benign prostatic hyperplasia: a lesson from 5-year serial follow-up data.
    Cho MC, Yoo S, Park J, Cho SY, Son H, Oh SJ, Paick JS.
    BJU Int; 2019 May 02; 123(5A):E34-E42. PubMed ID: 30582661
    [Abstract] [Full Text] [Related]

  • 17. Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia.
    Jhang JF, Liao CH, Kuo HC.
    Int J Clin Pract; 2014 Jun 02; 68(6):743-8. PubMed ID: 24471413
    [Abstract] [Full Text] [Related]

  • 18. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates.
    Wang M, Guo L, Duan F, Yuan K, Zhang G, Li K, Yan J, Wang Y, Kang H.
    BJU Int; 2016 Jan 02; 117(1):155-64. PubMed ID: 25851432
    [Abstract] [Full Text] [Related]

  • 19. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome.
    Park YW, Kim SB, Kwon H, Kang HC, Cho K, Lee KI, Kim YJ, Lee JH.
    Urology; 2013 Sep 02; 82(3):674-9. PubMed ID: 23850334
    [Abstract] [Full Text] [Related]

  • 20. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E, Bientinesi R, Marangi F, Totaro A, D'Addessi A, Racioppi M, Pinto F, Vittori M, Bassi P.
    BJU Int; 2012 Dec 02; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.